BTIG Research Issues Positive Forecast for vTv Therapeutics (NASDAQ:VTVT) Stock Price

vTv Therapeutics (NASDAQ:VTVT) had its target price lifted by stock analysts at BTIG Research from $49.00 to $57.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. BTIG Research’s target price points to a potential upside of 74.37% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Zacks Research downgraded vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.67.

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock opened at $32.69 on Thursday. The company has a market capitalization of $128.80 million, a PE ratio of -35.15 and a beta of 0.25. The company has a 50-day simple moving average of $33.90 and a two-hundred day simple moving average of $35.54. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. On average, equities analysts predict that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

Institutional Trading of vTv Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the fourth quarter valued at about $221,000. Geode Capital Management LLC raised its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth about $731,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.